<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129546">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02050776</url>
  </required_header>
  <id_info>
    <org_study_id>NGBSI-07</org_study_id>
    <nct_id>NCT02050776</nct_id>
  </id_info>
  <brief_title>Stem Cell Therapy in Limb Girdle Muscular Dystrophy</brief_title>
  <official_title>The Role of Cell Therapy in Modifying the Course of Limb Girdle Muscular Dystrophy- A Longitudinal 5-year Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurogen Brain and Spine Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neurogen Brain and Spine Institute</source>
  <oversight_info>
    <authority>India: Indian Council of Medical Research</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to study the effect of stem cell therapy on the course of the
      disease in patients with Limb Girdle Muscular Dystrophy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Functional Independence Measure</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Manual Muscle Testing</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Limb Girdle Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Stem Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>autologous bone marrow mononuclear cell transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous bone marrow mononuclear cell transplantation</intervention_name>
    <description>bone marrow derived mononuclear cells are administered intrathecally and intramuscularly in limb girdle muscular dystrophy patients</description>
    <arm_group_label>Stem Cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  males and females

          -  age group of 15 years and above

          -  limb girdle muscular dystrophy diagnosed on the basis of clinical presentation

          -  Electromyographic and Nerve Conduction velocity findings

        Exclusion Criteria:

          -  presence of respiratory distress

          -  presence of acute infections such as Human Immunodeficient Virus/Hepatitis B
             Virus/Hepatitis C Virus

          -  malignancies

          -  acute medical conditions such as respiratory infection, fever, hemoglobin less   than
             8, bleeding tendency, bone marrow disorder, left ventricular ejection fraction &lt; 30%

          -  pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alok K Sharma, M.S., M.Ch</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurogen Brain and Spine Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neurogen brain and spine institute</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400071</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Sharma A, Sane H, Badhe P, Gokulchandran N, Kulkarni P, Lohiya M, Biju H, Jacob VC. A clinical study shows safety and efficacy of autologous bone marrow mononuclear cell therapy to improve quality of life in muscular dystrophy patients. Cell Transplant. 2013;22 Suppl 1:127-38. doi: 10.3727/096368913X672136. Epub 2013 Sep 10.</citation>
    <PMID>24070109</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 30, 2014</lastchanged_date>
  <firstreceived_date>January 29, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophies, Limb-Girdle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
